The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose

Abstract

An ideal preparation for intravenous iron replacement therapy should balance effectiveness and safety. Compounds that release iron rapidly tend to cause toxicity, while large molecules can induce antibody formation and cause anaphylactic reactions. There is therefore a need for an intravenous iron preparation that delivers appropriate amounts of iron in a readily available form but with minimal side effects and thus with an excellent safety profile. In this paper, a review is given on the chemistry, pharmacology, and toxicology of ferric carboxymaltose (FCM, Ferinject®), a stable and robust complex formulated as a colloidal solution with a physiological pH.

The complex is gradually taken up mainly from the hepatic reticulo-endo-thelial system (RES), followed by effective delivery of iron to the endogeneous transport system for the haem synthesis in new erythrocytes, as shown in studies on the pharmacodynamics and pharmacokinetics with radio-labelled FCM. Studies with radio-labelled FCM also demonstrated a barrier function of the placenta and a low transfer of iron into the milk of lactating rats. Safety pharmacology studies indicated a favourable profile with regard to cardiovascular, central nervous, respiratory, and renal toxicity. A high maximum non-lethal dose was demonstrated in the single-dose toxicity studies. Furthermore, based on the No-Observed-Adverse-Effect-Levels (NOAELs) found in repeated-dose toxicity studies and on the cumulative doses administered, FCM has good safety margins. Reproductive and developmental toxicity studies did not reveal any direct or indirect harmful effects. No genotoxic potential was found in in vitro or in vivo studies. Moreover, antigenicity studies showed no cross-reactivity of FMC with anti-dextran antibodies and also suggested that FCM does not possess sensitizing potential. Lastly, no evidence of irritation was found in local tolerance studies with FCM.

This excellent toxicity profile and the high effectiveness of FCM allow the administration of high doses as a single infusion or bolus injection, which will enhance the cost-effectiveness and convenience of iron replacement therapy. In conclusion, FCM has many of the characteristics of an ideal intravenous iron preparation.

Key words

Anaemia - Ferinject® - Ferric carboxymaltose, chemistry, pharmacology, toxicology - Intravenous iron - Iron deficiency

• References

• 1 Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung. 1992; 42 (12) 1439-52
• 2 Geisser P, Rumyantsev V. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder. Arzneimittelforschung. 2010; 60 (6a) 373-385
• 3 Beshara S, Sorensen J, Lubberink M, Tolmachev V, Lang-strom B, Antoni G et al. Pharmacokinetics and red cell utilization of ⁵²Fe/⁵⁹Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol. 2003; 120 (5) 853-9
• 4 Pharmacology of a single dose of intravenously administered VIT-45 in anemic rats. Vifor (International) Inc. SR-1075/E01 2002
• 5 59Fe-VIT-45: Absorption, distribution and excretion studies in the anaemic rat after single intramuscular or single intravenous dosing. Vifor (International) Inc. VFR061 2005
• 6 59Fe-VIT-45: Absorption, distribution and excretion studies in the normal (nonanaemic) rat after single intramuscular or single intravenous dosing. Vifor (International) Inc. VFR060 2004
• 7 59Fe-VIT-45: Absorption, distribution and excretion studies in the dog after single intramuscular or single intravenous dosing. Vifor (International) Inc. VFR059 2004
• 8 Determination of the amount of degradation products of the ligand of VIT-45 using α-amylase and S9 fraction of rat liver homogenate. Vifor (International) Inc. SR1099-01/E02 2004
• 9 59Fe-VIT-45: Placental transfer and milk secretion studies in the rat after single intravenous dosing. Vifor (International) Inc. VFR062 2006
• 10 Malek A. In vitro studies of ferric carboxymaltose on placental permeability using the dual perfusion model of human placenta. Arzneimittelforschung. 2010; 60 (6a) 354-361
• 11 Intravenous administration of 59Fe-labelled VIT-45 to rat dams: transport of iron through the milk to the offspring. Vifor (International) Inc. SR-1077/E01 2003
• 12 VIT-45: Evaluation of respiratory parameters in the conscious rat using whole body bias flow plethysmography (single intravenous administration). Vifor (International) Inc. VFR068 2005
• 13 VIT-45: Assessment of effects on renal function in the conscious rat (single intravenous administration). Vifor (International) Inc. VFR069 2005
• 14 VIT-45: Assessment of effects on renal function in the conscious rat (single intravenous administration) (repeat study). Vifor (International) Inc. VFR086 2005
• 15 VIT-45: Irwin dose-range in rats, including body temperature and locomotor assessment (single intravenous administration). Vifor (International) Inc. VFR067 2005
• 16 VIT-45: Telemetric evaluation of cardiovascular effects in the conscious dog (single intravenous administration). Vifor (International) Inc. VFR066 2005
• 17 VIT-45: Telemetric evaluation of cardiovascular effects in twelve conscious Beagle dogs. Vifor (International) Inc. VFR099 2008
• 18 Iron dextrin complex: Acute intravenous toxicity to the mouse (highest non-lethal/lowest lethal dose). Vifor (International) Inc. VFR035 2000
• 19 Iron dextrin complex: Acute intravenous toxicity to the rat (highest non-lethal/lowest lethal dose). Vifor (International) Inc. VFR034 2000
• 20 Iron dextrin complex: Single dose pilot toxicity study by intravenous infusion administration to CD rats followed by a 7 day observation period. Vifor (International) Inc. VFR033 2002
• 21 Iron dextrin complex: Toxicity study by intravenous infusion administration to Beagle dogs for 13 weeks. Vifor (International) Inc. VFR032 2002
• 22 Toxicity and Histotoxicity of intravenously administered VIT-45 in NMRI mice. Vifor (International) Inc., SR-1026/E01 2002
• 23 Watanabe M, Hatanaka J, Asaoka S, Iyatomi A. Acute toxicity study with HIPPIRON in rats and mice. Nihon Tokusku Noyaku Seizo KK, Agricultural Chemicals Institute, Toxi-cological Research Laboratory. Report 223 1982;
• 24 Histology and distribution of iron of a single dose of intravenously administered VIT-45 in non-aneamic mice. Vifor (International) Inc.; TC-1073-01/E01 2008
• 25 Iron dextrin complex: Toxicity study by intravenous infusion administration to CD rats for 13 weeks. Vifor (International) Inc. VFR042 2002
• 26 VIT-45: Chronic toxicity study by intravenous (bolus) administration to CD rats three times per week for 26 weeks followed by a 6 week recovery period. Vifor (International) Inc. VFR072 2005
• 27 Iron dextrin complex: Toxicity study by intravenous infusion administration to Beagle dogs for 13 weeks. Vifor (International) Inc. VFR041 2002
• 28 VIT-45: Chronic toxicity study by intravenous (bolus) admin to Beagle dogs three times per week for 26 weeks followed by a 6 week recovery period. Vifor (International) Inc. VFR070 2005
• 29 VIT-45: Toxicity study by intravenous (bolus) administration to CD rats three times per week for 13 weeks. Vifor (International) Inc. VFR071 2005
• 30 Iron dextrin complex: Study of effects on fertility and early embryonic development to implantation in CD rats by intravenous infusion administration. Vifor (International) Inc. VFR050 2002
• 31 Iron dextrin complex: Preliminary study of embryo-fetal toxicity in the CD rat by intravenous infusion administration. Vifor (International) Inc. VFR048 2000
• 32 Iron dextrin complex: Study of effects on embryo-fetal toxicity in rabbits by intravenous infusion administration. Vifor (International) Inc. VFR049 2000
• 33 Developmental toxicity study on the effects of intravenous infusion of VIT-45 on embryo-fetal toxicity in rabbits, Luit-pold Pharmaceutical Inc. UBW0 0001 2006
• 34 Iron dextrin complex: Study of effects on pre- and post-natal development in CD rats by intravenous infusion administration. Vifor (International) Inc. VFR052 2002
• 35 Flodh H, Magnusson G, Malmfors T. Teratological, peri-and post-natal studies on Ferastral®, an iron-poly(sor-bitol-gluconic acid) complex. Scand J Haematol. 1977; 32 (Suppl) 69-83
• 36 Venofer. Study of effects on embryo-foetal toxicity in CrL:CD®BR rat by intravenous infusion. Vifor (International) Inc.VFR016 1997
• 37 Venofer. Study of effects on embryo-foetal toxicity in the rabbit by intravenous infusion. Vifor (International) Inc. VFR026 1999
• 38 Fe dextrinate: bacterial mutation assay. Vifor (International) Inc. VFR029 1999
• 39 Fe dextrinate: In vitro mammalian chromosome aberration test in human lymphocytes. Vifor (International) Inc. VFR028 1999
• 40 Fe dextrinate: Mammalian cell mutation assay. Vifor (International) Inc. VFR030 1999
• 41 Fe dextrinate: Mouse micronucleus test. Vifor (International) Inc. VFR031 1999
• 42 Dextran antigenicity to the rabbit. Vifor (International) Inc. VFR043 2000
• 43 VIT-45: Intravenous tolerance in the rabbit. Vifor (International) Inc. VFR063 2003
• 44 VIT-45: Local tolerance study in the rabbit following intravenous injection, Vifor (International) Inc. VFR0101;2007
• 45 VIT-45: Perivenous tolerance in the rabbit. Vifor (International) Inc. VFR055 2003
• 46 VIT-45: Local tolerance study in the rabbit following perivenous injection, Vifor (International) Inc. VFR0108 2007
• 47 VIT-45: Intra-arterial tolerance in the rabbit. Vifor (International) Inc. VFR054 2003
• 48 VIT-45: Haemocompatibility test: Method of Prieur et al. Vifor (International) Inc. VFR065 2004
• 49 Bailie S. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications. Arzneimittelforschung. 2010; 60 (6a) 386-398
• 50 Qunibi WY. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung. 2010; 60 (6a) 399-412
• 51 Periodic Safety Update Report: Ferinject®. Period covered 18 June 2008-17 December 2008. Vifor (International) Inc. PVZ-VIT45/E03; 10 February 2009